Astellas Pharma's VYLOY Receives FDA Approval For Treatment Of Advanced Gastric And GEJ Cancer
Astellas Pharma Inc. (ALPMY, ALPMY) said that the U.S. Food and Drug Administration has approved VYLOY (zolbetuximab-clzb) in ...
Medscape7 小时
FDA OKs Zolbetuximab for Gastric, Gastroesophageal Cancer
FDA also approved the Ventana CLDN18 (43-14A) RxDx Assay, from Ventana Medical Systems, Inc. and Roche Diagnostics, to ...
precisionmedicineonline8 小时
FDA Approves Astellas' Vyloy, Chemo in First-Line CLDN18.2-Positive Gastric Cancer With ...
Vyloy is the first CLDN 18.2-targeted treatment to reach the US market alongside Roche's Ventana CLDN18 RxDx Assay for identifying eligible patients.
Too Old to Operate8 小时
In Advanced RCC, Rechallenging Patients With ICIs May Not Be Beneficial, but Tivozanib ...
Rechallenging patients with ICIs may not be beneficial in advanced RCC, but Tivozanib monotherapy shows promise as an ...
Le Lézard9 小时
Astellas' VYLOYtm (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced ...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved VYLOYtm (zolbetuximab-clzb) in combination ...
Medpage Today on MSN23 小时
Novel Targeted Drug Approved for Stomach Cancers
The FDA approved zolbetuximab (Vyloy), a claudin 18.2 (CLDN18.2)-directed cytolytic antibody, in combination with ...